SKYE实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases...

Stats
今日成交量	34 863.00
平均成交量	46 458.00
市值	12.65B
EPS	$0 ( 2024-03-31 )
下一个收益日期	( $0 ) 2024-05-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.150
ATR14	$0.0560 (0.43%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-13	5am Partners Vii, Llc	Buy	450 000	Common Stock
2024-03-13	Schwab Andrew J.	Buy	450 000	Common Stock
2024-02-29	Grayson Paul A.	Buy	100 000	Common Stock
2024-02-29	Grayson Paul A.	Buy	35 000	Stock Option (Right to Buy)
2024-02-29	Charych Deborah H.	Buy	35 000	Stock Option (Right to Buy)

INSIDER POWER
98.76
Last 83 transactions
Buy: 1 749 377 489 \| Sell: 16 641 486

音量相关性

長: -0.42 (neutral)

短: 0.47 (neutral)

Signal:(53.944) Neutral

Skye Bioscience, Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Skye Bioscience, Inc. 相关性 - 货币/商品

0.06
( neutral )

-0.20
( neutral )

0.00
( neutral )

0.14
( neutral )

0.00
( neutral )

0.25
( neutral )

Skye Bioscience, Inc. 财务报表

Annual	2022
营收:	$0
毛利润:	$-114 998 (0.00 %)
EPS:	$-9.82

FY	2022
营收:	$0
毛利润:	$-114 998 (0.00 %)
EPS:	$-9.82

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.0200

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.0300

Financial Reports:

No articles found.

Skye Bioscience, Inc.

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.